Home About ATSDR Press Room A-Z Index Glossary Employment Training Contact Us CDC  
ATSDR/DHHS Agency for Toxic Substances and Disease Registry Agency for Toxic Substances and Disease Registry Department of Health and Human Services ATSDR en Español

Search:

Section Contents
 
Learning Objectives
Introduction
Signs and Symptoms
Treatment
Key Points
Progress Check
 
Case Contents
 
Table of Contents
Cover Page
How to Use the Course
Initial Check
Mass Casualty Events
Cholinesterase Inhibitors
Pathological Conditions
Cholinergic Toxidrome
Nicotinic Receptors
Muscarinic Receptors
Nicotinic/Muscarinic Mixture
Signs and Symptoms
Laboratory Tests
Differential Diagnosis
Pediatric Cases
Exposure History
RBC & Serum Tests
Inhibitors & Byproducts
Management Strategies
Secondary Exposure
Supportive Care
First-Line Medications
Medications: Atropine
Medications: Pralidoxime
Medications: Diazepam
Antidote Stocking
Deprecated Treatments
Medico-Legal Issues
Intermediate Syndrome
Delayed Neuropathy
Other Issues
Posttest
Literature Cited
 
Related Documents
 
MMG: Nerve Agents
ToxFAQs™: Nerve Agents
 
Case Studies (CSEM)
 
CSEM Home
Continuing Education
Online Registration
 
ATSDR Resources
 
ATSDR en Español
Case Studies (CSEM)
Exposure Pathways
HazDat Database
Health Assessments
Health Statements
Interaction Profiles
Interactive Learning
Managing Incidents
Medical Guidelines
Minimal Risk Levels
Priority List
ToxFAQs™
ToxFAQs™ CABS
Toxicological Profiles
Toxicology Curriculum
 
External Resources
 
CDC
eLCOSH
EPA
Healthfinder®
Medline Plus
NCEH
NIEHS
NIOSH
OSHA
 

Agency for Toxic Substances and Disease Registry 
Case Studies in Environmental Medicine (CSEM) 

Cholinesterase Inhibitors
Including Insecticides and Chemical Warfare Nerve Agents
Part 7: Organophosphorus Ester-Induced Chronic Neurotoxicity (OPICN)


Learning Objectives

Upon completion of this section, you should be able to describe:

  • Our current level of understanding about the association of OPICN and asymptomatic exposures to cholinesterase inhibitors.
  • Currently recommended treatment options.

Introduction

Organophosphorus ester-induced chronic neurotoxicity (OPICN) --- also called chronic organophosphate-induced neuropsychiatric disorder (COPIND) --- is a set of long-term, persistent, chronic neuropsychiatric findings that some have attributed to cholinesterase inhibitor toxicity.


Signs and Symptoms

Some of the signs and symptoms that have been ascribed to this condition include (Jamal 1997; Abou-Donia 2003)

  • Apathy
  • Decreased visual memory
  • Impaired vigilance
  • Reduced abstract reasoning
  • Anxiety
  • Depression
  • Increased social isolation
  • Reduced fine motor coordination
  • Confusion
  • Dizziness
  • Insomnia
  • Reduced vibrotactile sensitivity
  • Decreased academic skills
  • Emotional lability
  • Irritability
  • Short-term memory deficits
  • Decreased verbal attention
  • Fatigue
  • Problems with concentration
  • Slowing of reaction time

Controversy

There is a great deal of debate surrounding the subject of Organophosphorus ester-induced chronic neurotoxicity (OPICN).  (Jamal 1997; Bateman 1999; Vale 1999; Colosio, Tiramani et al. 2003) It has been argued that the condition can follow either an acute, symptomatic exposure or repeated, asymptomatic exposures. (Abou-Donia 2003)

A number of the key studies supporting this argument, particularly those relating to asymptomatic exposures, have been criticized on methodological grounds.  (Bateman 1999; Vale 1999; Colosio, Tiramani et al. 2003) In particular, determination of exposure in most studies has been based on recall rather than on objective measurements. This method of assessing exposure has not been shown to be very reliable. (Boyer, Templin et al. 1995) In addition, a number of the studies have been based on recall of exposures to pesticides in general, rather than specifically to cholinesterase inhibitors.

Some have pointed out that neuropsychiatric findings following severe acute exposures are consistent with damage from seizures and hypoxia, and may not represent a specific toxic effect. (Vale 1999) However, current evidence cannot rule out such a toxic effect, and better-designed studies are needed to resolve the debate. (Colosio, Tiramani et al. 2003)


Treatment

No specific treatment has been identified.


Key Points

  • Studies suggesting that OPICN result from asymptomatic, chronic exposure to cholinesterase inhibitors have suffered from methodological problems.
  • Clinical findings attributed to OPICN are consistent with brain damage due to hypoxia and seizures and my not represent a specific toxic effect.
  • No specific treatment for OPICN has yet been identified.

Progress Check

50. Which of the following is correct about organophosphorus ester-induced chronic neurotoxicity (OPICN) (Choose ALL correct answers)

A. It has been established by objective measurement of exposures in humans that this condition occurs with repeated or chronic asymptomatic exposures to cholinesterase inhibitors.
B. Is consistent with damage from seizures and hypoxia.
C. Is controversial.
D. None of the above.

Answer:

To review relevant content, see Controversy in this section.


51. Effective treatment for OPICN includes (Choose ALL correct answers)

A. Neurotarget esterase.
B. 2-PAM.
C. Atropine.
D. None of the above.

Answer:

To review relevant content, see Treatment in this section.


Previous Section

Next Section

Revised 2007-10-16.